OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Opinion on Drug Metabolism & Toxicology is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins	76
The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer	63
Crosstalk of physiological pH and chemical pKa under the umbrella of physiologically based pharmacokinetic modeling of drug absorption, distribution, metabolism, excretion, and toxicity	54
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders	47
Experts’ opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond	43
Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials	43
Prodrugs and nanomicelles to overcome ocular barriers for drug penetration	42
Albumin-based drug designs for pharmacokinetic modulation	42
Antisense oligonucleotides: absorption, distribution, metabolism, and excretion	41
High-throughput PBTK models for in vitro to in vivo extrapolation	40
ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?	36
Antibiotic resistance propagation through probiotics	36
Analyzing FDA-approved drugs for compliance of pharmacokinetic principles: should there be a critical screening parameter in drug designing protocols?	34
Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson’s disease	33
Update on drug-drug interaction at organic cation transporters: mechanisms, clinical impact, and proposal for advancedin vitrotesting	33
The pharmacokinetics of antibiotics in cystic fibrosis	33
Alterations in drug disposition in older adults: a focus on geriatric syndromes	31
An update on drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors	29
The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis	29
Current opinion on the pharmacogenomics of paclitaxel-induced toxicity	28
Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer’s disease	27
Tumor grafted – chick chorioallantoic membrane as an alternative model for biological cancer research and conventional/nanomaterial-based theranostics evaluation	27
Drug metabolism in the lungs: opportunities for optimising inhaled medicines	27
Tenofovir alafenamide use in pregnant and lactating women living with HIV	26
Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis	25